Does the use of recombinant AAV5 in pulmonary gene therapy lead to lung damage?

S. V. Martini, S. S. Fagundes, A. C. Schmidt, M. Avila, D. S. Ornellas, V. T. Ribas, H. Petrs-Silva, R. Linden, D. S. Faffe, S. E. Guggino, P. R.M. Rocco, W. A. Zin, M. M. Morales

Research output: Contribution to journalArticlepeer-review


This study investigated whether repeated administration of recombinant adeno-associated virus type 5 (rAAV5) to the airways induces inflammatory processes in the lungs of BALB/c-mice, with mechanical and histologic changes. Saline was instilled intratracheally in the control group, and rAAV5-green fluorescence protein (GFP) (4 × 1011 particles) in the virus group (VR). These groups were subdivided into four subgroups: one dose analyzed 3 weeks later (VR1d3w) and two doses analyzed 1 (VR2d1w), 2 (VR2d2w) and 3 weeks (VR2d3w) after the second dose. Lung morphometry, mechanical parameters, airway responsiveness, rAAV5-GFP transduction and the expression of inflammatory cytokines were investigated. No significant differences in lung mechanics, airway responsiveness, and morphometry were observed. Re-administration of rAAV5 vector resulted in a decrease in GFP mRNA expression in the VR2d3w group. There was no evidence of inflammatory response or apoptosis in any group. rAAV5 did not induce an inflammatory process, mechanical or morphometric changes in the lungs. AAV5 may be an appropriate vector for lung gene therapy.

Original languageEnglish (US)
Pages (from-to)203-209
Number of pages7
JournalRespiratory Physiology and Neurobiology
Issue number3
StatePublished - Sep 30 2009
Externally publishedYes


  • Adeno-associated virus type 5
  • Gene therapy
  • Pulmonary mechanics
  • Vector

ASJC Scopus subject areas

  • Neuroscience(all)
  • Physiology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Does the use of recombinant AAV5 in pulmonary gene therapy lead to lung damage?'. Together they form a unique fingerprint.

Cite this